Hepatitis B virus reactivation associated with temozolomide for malignant glioma: A case report and recommendation for prophylaxis

International Journal of Clinical Oncology

Volumn 17, Issue 3, 2012, Pages 290-293

  Fujimoto, Yasunori ^a   Hashimoto, Naoya ^a   Kinoshita, Manabu ^a   Miyazaki, Yuko ^a   Tanaka, Satoshi ^a   Yakushijin, Takayuki ^a   Takehara, Tetsuo ^a   Kagawa, Naoki ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis B; Malignant glioma; Nucleoside analog; Prophylaxis; Reactivation

Indexed keywords

ENTECAVIR; GADOLINIUM; HEPATITIS B SURFACE ANTIGEN; INTERFERON; METHYLPREDNISOLONE; TEMOZOLOMIDE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; DRUG PULSE THERAPY; FATIGUE; FEMALE; GLIOMA; HEADACHE; HEPATITIS B VIRUS; HUMAN; LATERAL BRAIN VENTRICLE; LIVER FUNCTION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIVIRAL AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CARRIER STATE; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; MIDDLE AGED; VIRUS ACTIVATION;

EID: 84862840773     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0294-3     Document Type: Article

References (23)

1. Galbraith RM, Eddleston AL, William R et al (1975) Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug chemotherapy. Lancet 2:528-530
2. Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with hae-matological malignancies. Br J Haematol 136:699-712
3. Law JK, Ho JK, Hoskins PJ et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085-1089
4. Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307
5. Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311
6. Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblas-toma multiforme treated with concomitant radiation plus tem-ozolomide followed by adjuvant temosolomide. J Clin Oncol 20:1375-1382
7. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987-996
8. Chheda MG, Drappatz J, Greenberger NJ et al (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 68:955-956
9. Grewal J, Dellinger CA, Yung WKA (2007) Fatal reactivation of hepatitis B with temozolomide. N Eng J Med 356:1591-1592
10. Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270-275
11. Markovic S, Drozina G, Vovk M et al (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lym-phoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925-2930
12. Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24: 1003-1016
13. Lok ASF, Liang RHS, Chiu EKW et al (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188
14. Tur-Kaspa R, Burk RD, Shaul Y et al (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627-1631
15. Pei SN, Chen CH, Lee CM et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HbsAg-negative patients. Ann Hematol 89:255-262
16. Lok ASF, NcMahon BJ (2007) Chronic hepatitis B. Heapatology 45:507-539
17. Lok ASF, NcMahon BJ (2009) Chronic hepatitis B: update 2009. Heapatology 50:661-662
18. Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705-712
19. Tsubouchi H, Kumada H, Kiyosawa K et al (2009) Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection-Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis (in Japanese). Kanzo 50:38-42
20. Idilman R (2006) Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 55:1208-1209
21. World Health Organization (2008) Hepatitis B (Fact sheet, No. 204). Geneva, WHO. http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed August 2008
22. Tanaka J, Koyama T, Mizui M et al (2011) Total number of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology. doi:10.1159/000324525
23. Fujisaki S, Yokomaku Y, Shiino T et al (2011) Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49:1017-1024